CMC Consulting, Contract Research
Total Trials
19
As Lead Sponsor
12
As Collaborator
7
Total Enrollment
5,311
NCT03515252
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 26, 2005
Completion: Jun 7, 2007
NCT03592706
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Phase: Phase 2/3
Start: Dec 31, 2009
Completion: Aug 31, 2021
NCT03499834
A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Phase: Phase 2
Start: Dec 5, 2017
Completion: Feb 16, 2020
NCT04417465
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
Role: Collaborator
Start: Jun 3, 2020
Completion: Aug 21, 2025
NCT04777994
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Start: Mar 9, 2021
Completion: Oct 31, 2026
NCT04948645
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Start: Sep 22, 2021
Completion: Jul 15, 2025
NCT05077332
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Start: Dec 29, 2021
Completion: Dec 31, 2025
NCT05077969
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
Completion: Jul 8, 2022
NCT05085574
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
Start: Feb 7, 2023
Completion: Feb 7, 2023
NCT05757141
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Phase: Phase 1/2
Start: Mar 13, 2023
Completion: Nov 30, 2029
NCT05740813
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Start: Mar 23, 2023
Completion: Oct 3, 2024
NCT05763459
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
Start: Mar 24, 2023
Completion: Jun 2, 2023
NCT06145607
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
Start: Dec 19, 2023
Completion: Feb 26, 2024
NCT06310876
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
Start: Mar 14, 2024
Completion: Jun 26, 2024
NCT06425003
Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
Start: May 21, 2024
Completion: Jul 12, 2024
NCT06698926
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
Start: Nov 11, 2024
NCT06902558
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Start: Jun 9, 2025
Completion: Aug 31, 2029
NCT07190105
Vagal Approaches on Long COVID-19
Phase: N/A
Start: Sep 30, 2025
Completion: Nov 30, 2025
Loading map...